Nauck MA, DAlessio DA (2022) Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction
Other drugmakers, such as Eli Lilly and Pfizer, are developing their own GLP-1s in a bid to capitalize on a weight loss drug market that some analysts project could be worth $200 billion by 2030
GIP also stimulates bone formation and inhibits bone resorption [38], but we dont have any clinical evidence to date of an effect on bone preservation with a GLP- 1/GIP dual agonist for weight loss
[DOI] [PubMed] [Google Scholar] 4.Jain S.K., Velusamy T., Croad J.L., Rains J.L., Bull R
Tumour necrosis factor (TNF) released from microglia or perivascular macrophages activates the c-Jun N-terminal kinase (JNK) and inhibitor of B alpha/nuclear factor B (IB/NF-B) signalling pathways, thereby amplifying neuroinflammatory responses throughout the brain parenchyma [8]
These targeted therapies can focus directly on tumor cells, significantly reducing toxicity